Evidence-Based Laboratory Medicine: Laboratory Medicine Best Practices Systematic Review Recommendations Evaluation
The purpose of the project is to evaluate the clinical laboratory best practice recommendation for reducing blood sample hemolysis rates developed through the Laboratory Medicine Best PracticesTM (LMBPTM) Initiative of the Centers for Disease Control and Prevention. This recommendation was the product of a systematic review for evidence of effectiveness for practices to reduce hemolysis and was developed using the A6 Method established through the LMBPTM Initiative. The current study seeks to measure the extent of improvement that results from implementation of this evidence-based best practice recommendation compared to existing (current) practices to reduce hemolysis. The design of the recommendation evaluation plan should be based on the A6 Method, described elsewhere in this document, and consider evidence of effectiveness as defined by laboratory quality indicators, patient outcomes, and cost analyses consistent with national health care priorities for improving public health. The LMBPTM recommendation for reduction of blood sample hemolysis rates will be evaluated through replication as described. One applicant will be awarded. This single award can be implemented as a study conducted in a single institution, measuring one or more settings within the institution, or multiple settings within affiliated facilities of a health system. The budget should reflect study design complexity. The purpose is limited to quality improvement associated with delivering healthcare, and the associated measuring and reporting of performance data.
General information about this opportunity
Last Known Status
Deleted 06/29/2013 (Archived.)
Program Number
CDC-RFA-OE13-1303
Federal Agency/Office
Agency: Department of Health and Human Services
Office: CENTERS FOR DISEASE CONTROL
Type(s) of Assistance Offered
Cooperative Agreement
Number of Awards Available
1
Who is eligible to apply/benefit from this assistance?
Applicant Eligibility
C. Eligibility Information 1. Eligible Applicants: • American Indian/Alaska Native tribal governments (federally recognized or state-recognized) • American Indian/Alaska native tribally designated organizations • Alaska Native health corporations • Colleges • Community-based organizations • Faith-based organizations • Hospitals • Nonprofit with 501C3 IRS status (other than institution of higher education) • Nonprofit without 501C3 IRS status (other than institution of higher education) • Political subdivisions of States (in consultation with States) • Research institutions (that will perform activities deemed as non-research) • State and local governments or their Bona Fide Agents (this includes the District of Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of the Northern Marianna Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau) . • Tribal epidemiology centers • Universities • Urban Indian health organizations
What is the process for applying and being award this assistance?
Application Procedure
•Letter of Intent Deadline Date: May 1, 2013 •Application Deadline Date: May 30, 2013, 11:59 p.m. U.S. Eastern Time, on www.grants.gov
Deadlines
05/30/2013
Other Assistance Considerations
Formula and Matching Requirements
This program does not have cost sharing or matching requirements.
Who do I contact about this opportunity?
Headquarters Office
CDC Procurement and Grants Office
(PGO) Technical Information Management Section (TIMS)
Phone: 770-488-2700
E-mail: pgotim@cdc.gov
E-mail Address
pgotim@cdc.gov
Financial Information
Obligations
$400,000.00
Range and Average of Financial Assistance
Awards up to $200,000.00
